Company Dossier · Health Care
Chemed Corporation
- Russell 1000
- MidCap 400
What Chemed Corporation is doing, read from its filings, its own words and the news, with every figure dated and sourced. Not investment advice: no ratings, no price targets.
Open the full company record in Palanor: guidance, KPIs, ownership, calls, prices →
The latest read
Computed from the data on Oct 22, 2026. Every figure links back to its source in the sections below.
- Revenue over the four quarters to June 30, 2026: $2.60 billion, up 3.6% from a year earlier.SEC EDGAR filings (XBRL)
- Free cash flow (operating cash flow minus capital expenditure) over the four quarters to June 30, 2026: $0.32 billion, down 14% from a year earlier.SEC EDGAR filings (XBRL)
- Capital expenditure over the four quarters to June 30, 2026: $0.07 billion, up 17% from a year earlier.SEC EDGAR filings (XBRL)
- Share buybacks in the fiscal year to December 31, 2025: $0.43 billion.SEC EDGAR filings (10-K)
- Latest earnings call or results release (July 29, 2026): sentiment 0.70 on a −1 to +1 scale (confident, opportunity-framed), confidence 0.85 of 1.Palanor Discourse
- Guidance in the last 90 days: 1 outlook figure raised, 0 lowered, 2 held.Guidance Ledger (8-K results releases)
- Latest annual report (filed February 27, 2026): 1 risk factor added, 0 removed.Risk Factor Changes (10-K Item 1A)
- Insiders were net sellers in Q3 2026: $4.8 million on the open market.SEC Form 4
- 531 institutional managers reported a position at June 30, 2026 (+40 on the quarter before).SEC Form 13F
- H-1B filings certified in Q1 2026: 2 (2 a year earlier).U.S. Department of Labor (OFLC)
Company Posture
How Company Posture is measured →Company Posture covers S&P 500 companies.
Credit
How these are built →No bond term sheets or tagged debt on file for Chemed Corporation yet.
Charts
Live charts: each one redraws from today’s data and has an image link to paste into a document or slide.
Cash flow
Capital returned and raised
What the company says
Hiring and ownership
Filings and records
The last two years of notable 8-Ks, offerings, annual reports, federal awards, lobbying reports, patents and other public records, newest first.
- Oct 20, 2026LobbyingLobbying report (VITAS HEALTHCARE CORPORATION)third_quarter 2026 · $0.2 million
- Oct 20, 2026LobbyingLobbying report (INLET STRATEGIES)third_quarter 2026 · $0.0 million
- Oct 19, 2026LobbyingLobbying report (THE NICKLES GROUP, LLC)third_quarter 2026 · $0.1 million
- Jul 20, 2026LobbyingLobbying report (VITAS HEALTHCARE CORPORATION)second_quarter 2026 · $0.2 million
- Jul 20, 2026LobbyingLobbying report (INLET STRATEGIES)second_quarter 2026 · $0.0 million
- Jul 20, 2026LobbyingLobbying report (THE NICKLES GROUP, LLC)second_quarter 2026 · $0.1 million
- May 19, 20268-KShareholder vote resultsItem 5.07
- Apr 20, 2026LobbyingLobbying report (VITAS HEALTHCARE CORPORATION)first_quarter 2026 · $0.2 million
- Apr 20, 2026LobbyingLobbying report (THE NICKLES GROUP, LLC)first_quarter 2026 · $0.1 million
- Apr 13, 20268-KMaterial agreement signedItem 1.01
- Feb 27, 202610-KAnnual report (10-K)1 risk factors added, 0 removed
- Jul 29, 20258-KDirector or officer changeItem 5.02
- May 20, 20258-KShareholder vote resultsItem 5.07
- Feb 28, 202510-KAnnual report (10-K)0 risk factors added, 0 removed
- Feb 29, 202410-KAnnual report (10-K)0 risk factors added, 1 removed
Peers
Companies in the same industry in the S&P 500, Russell 1000 or MidCap 400, closest in revenue first. Trailing twelve months, from SEC filings.
| Company | Revenue | Free cash flow | Through |
|---|---|---|---|
| Quest Diagnostics DGX | $11.6B | $1.4B | Jun 30, 2026 |
| DaVita DVA | $14.0B | $1.6B | Jun 30, 2026 |
| Labcorp LH | $14.3B | $1.2B | Jun 30, 2026 |
| Cigna CI | $282B | — | Jun 30, 2026 |
| CVS Health CVS | $415B | $11.8B | Jun 30, 2026 |
| Bio-Rad Laboratories BIO | $2.6B | $0.3B | Jun 30, 2026 |
| Hims & Hers Health HIMS | $2.6B | $0.1B | Jun 30, 2026 |
| Royalty Pharma RPRX | $2.5B | — | Jun 30, 2026 |
Identity
- SEC CIK
- 19584
- Wikidata
- Q106241500